Author

T. Bagci-Onder

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6 Bioengineering· 1 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Research Focus:drug response / drug discovery· 5 Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 3 Assay:bulk RNA-seq· 2 Assay:ChIP-seq· 2 Approach:genetic perturbation / CRISPR· 2 Approach:statistical model· 2

Frequent Co-Authors

A. Kayabolen· 4 shared A. Cingoz· 3 shared N. A. Lack· 3 shared T. Morova· 3 shared A. C. Aksu· 2 shared A. P. Cribbs· 2 shared E. Y. Kala· 2 shared F. Seker-Polat· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Kayabolen

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

ACE2-Coated Virus-Like Particles Effectively Block SARS-CoV-2 Infection

C. Bayraktar, A. Kayabolen, A. Odabas, A. Durgun, I. Kok, K. Sevinc, A. Supramaniam, A. Idris, T. Bagci-Onder

This paper develops ACE2-coated virus-like particles (ACE2-VLPs) that effectively neutralize SARS-CoV-2, including variants, and show superior efficacy compared to ACE2-expressing extracellular vesicles.

bioRxiv · Sep 19, 2023 · PreprintBioengineering

HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI/SNF complex

S. Lingadahalli, B. E. Fazlioglu, U. B. Altintas, A. Cingoz, E. Tekoglu, I. P. L. Yu, H. Andomat, I. Kulac, T. Morova, K. Xiao, U. M. Dikbas, M. Gleave, L. Fazli, P. Cejas, H. Long, , N. A. Lack

This study shows HOXB13 promotes prostate cancer proliferation by altering chromatin accessibility through interactions with the SWI/SNF complex, particularly in AR-negative castration-resistant prostate cancer.

bioRxiv · Sep 4, 2023 · PreprintCancer Biology

Exploiting Epigenetic Targets to Overcome Taxane Resistance in Prostate Cancer

B. Cevatemre, I. Bulut, B. Dedeoglu, A. Isiklar, H. Syed, O. Yedier Bayram, T. Bagci-Onder, C. Acilan Ayhan

This study identifies BRPF reader proteins and epigenetic regulators as targets to overcome taxane resistance in prostate cancer by reversing ABCB1-mediated efflux and restoring taxane susceptibility.

bioRxiv · Aug 10, 2023Cancer Biology

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

E. Ozyerli-Goknar, E. Y. Kala, A. C. Aksu, I. Bulut, A. Cingoz, S. Nizamuddin, M. Biniossek, F. Seker-Polat, T. Morova, C. Aztekin, S. H. A. Kung, H. Syed, N. Tuncbag, M. Gonen, M. Philpott, , T. Bagci-Onder

This study uses CRISPR/Cas9 screens to identify ASH2L as a key regulator of glioblastoma cell survival, with downstream effects on cell cycle and apoptosis.

bioRxiv · Aug 17, 2022 · PreprintCancer Biology

Chronically radiation-exposed survivor glioblastoma cells display poor response to Chk1 inhibition

N. Pinarbasi Degirmenci, I. Sur-Erdem, V. Akcay, Y. Bolukbasi, U. Selek, I. Solaroglu, T. Bagci-Onder

This study shows that glioblastoma cells surviving chronic radiation upregulate DNA repair genes and are less sensitive to Chk1 inhibition, especially under hypoxia.

bioRxiv · Apr 16, 2022 · PreprintCancer Biology

EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities

O. Yedier-Bayram, B. Gokbayrak, A. C. Aksu, A. D. Cavga, A. Kayabolen, E. Y. Kala, G. Karabiyik, R. Gunsay, T. Morova, F. Uyulur, N. A. Lack, T. T. Onder, T. Bagci-Onder

The paper introduces EPIKOL, a CRISPR-Cas9 library targeting epigenetic modifiers, and demonstrates its utility in identifying cancer-specific epigenetic vulnerabilities in breast and prostate cancer.

bioRxiv · May 14, 2021Cancer Biology

The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies

S. Durdagi, T. Avsar, M. D. Orhan, M. Serhatli, B. K. Balcioglu, H. U. Ozturk, A. Kayabolen, Y. Cetin, S. Aydinlik, T. Bagci-Onder, S. Tekin, H. Demirci, M. Guzel, A. Akdemir, S. Calis, , Y. Yumak

This paper shows Montelukast inhibits SARS-CoV-2 by targeting both Spike/ACE2 and main protease through in silico and in vitro studies.

bioRxiv · Dec 26, 2020Biophysics

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

A. Kayabolen, E. Yilmaz, G. N. Sahin, F. Seker-Polat, A. Cingoz, B. Isik, S. Acar, S. Karahuseyinoglu, H. Wakimoto, D. P. Cahill, I. Solaroglu, A. P. Cribbs, U. Oppermann, T. Bagci-Onder

This study identifies GSK-J4 and Belinostat as effective therapies for IDH1-mutant glioma by targeting KDM6A/B and HDACs, showing synergistic effects in vitro and in vivo.

bioRxiv · Nov 26, 2020 · PreprintCancer Biology